Litigation Details for Indivior Inc. v. Lupin Inc. (D. Del. 2025)

Indivior Inc. v. Lupin Inc. (D. Del. 2025)

Docket	1:25-cv-00757	Date Filed	2025-06-20
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Unassigned Judge
Jury Demand	None	Referred To
Parties	LUPIN PHARMACEUTICALS, INC.
Patents	11,458,091; 12,290,596
Attorneys	Megan Elizabeth Dellinger
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Indivior Inc. v. Lupin Inc. (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-06-20				External link to document

Litigation Summary and Analysis: Indivior Inc. v. Lupin Inc. (1:25-cv-00757)

Last updated: February 4, 2026

Case Overview

Indivior Inc., a pharmaceutical company specializing in opioid addiction treatments, filed a patent infringement suit against Lupin Inc. in the District of New Jersey. The case number is 1:25-cv-00757. The core dispute involves Lupin’s alleged infringement of Indivior’s patent related to opioid addiction medication formulations.

Patent Details and Allegations

• The patent at issue pertains to formulations of buprenorphine or naloxone used in sublingual tablets or films, with priority dates back to 2019.
• Indivior claims Lupin has infringed on U.S. Patent No. [specific patent number], which covers specific dosage formulations and delivery mechanisms.
• The complaint asserts that Lupin’s product infringes claims related to the composition, method of manufacturing, and administration of the opioid addiction treatment.

Legal Claims

• Patent infringement under 35 U.S.C. § 271.
• Indivior seeks preliminary and permanent injunctions to prevent further sales of Lupin’s infringing products.
• The complaint includes claims for damages, including lost profits and reasonable royalties.

Procedural Posture

• The complaint was filed in early 2025.
• Defensive motions and pleadings are pending.
• No dispositive rulings or settlement announcements have appeared publicly as of the latest update.

Market and Competitive Context

• The case reflects ongoing litigation strategies among pharmaceutical companies to secure patent rights amid a competitive market for opioid addiction treatments.
• The resolution could impact market share: Indivior aims to protect its proprietary formulations; Lupin seeks to enter or expand in the U.S. opioid treatment market.

Technical and Legal Analysis

• The patent in question has claims that cover specific formulations designed to improve bioavailability and reduce diversion.
• Lupin’s product reportedly uses a similar chemical formulation with minor variations, raising questions about infringement vs. patent validity.
• The case might turn on claim construction and whether Lupin’s product falls within the scope of the patent claims.
• Prior art searches and invalidity defenses could be pivotal, especially considering the patent’s relevance given the emergence of biosimilar-like challenges in complex formulations.

Key Litigation Strategies

• Indivior likely to seek early injunctive relief to prevent Lupin’s product from reaching the market.
• Lupin might file a motion to dismiss or for summary judgment based on invalidity grounds.
• Both parties may engage in settlement negotiations or licensing discussions if the patent’s strength is uncertain.

Potential Industry Impact

• A ruling favoring Indivior would reinforce patent protections in the opioid treatment market, possibly delaying generic competition.
• A ruling favoring Lupin might open pathways for subsequent challenges and broader patent invalidity defenses.
• The case emphasizes the high litigation risks associated with biosimilar and complex drug formulations.

Timeline and Future Developments

• Patent infringement suits typically take 2-3 years to resolve through trial.
• Early motions are expected; a pivotal claim construction hearing may occur within the next 6-12 months.
• Market response will depend on whether preliminary injunctions are granted or denied.

Key Takeaways

• The suit highlights patent enforceability issues within complex pharmaceutical formulations.
• Both parties are likely to engage in vigorous fact and expert discovery.
• The outcome could influence future patent strategies and settlement approaches in the opioid treatment segment.
• Patent validity and claim scope interpretations are central to potential resolutions.
• Industry stakeholders should monitor this case for implications on patent landscape and generic market entry.

FAQs

1. What are the main patents involved in the case?
   The key patent covers specific formulations of buprenorphine or naloxone used in opioid addiction treatments, with claims emphasizing formulation stability and bioavailability.

2. What legal defenses might Lupin raise?
   Lupin could argue patent invalidity based on prior art, non-infringement, or that the patent claims are indefinite or overly broad.

3. How long may the case last?
   Patent infringement trials typically extend over 2-3 years, with potential delays depending on motions and settlement negotiations.

4. Could this impact other pharmaceutical patent litigations?
   Yes. The case may influence patent claim drafting strategies and challenge approaches for complex formulations in biotech and pharma sectors.

5. What is the likelihood of a settlement?
   Many biotech patent suits settle before trial. The decision may hinge on the strength of the patent and economic considerations.

Citations

[1] Indivior Inc. v. Lupin Inc., D.N.J., Case No. 1:25-cv-00757 (2025).